A Single Arm, Multicenter, Phase II Trial of RAD001 [everolimus] as Monotherapy in the Palliative Treatment of Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma After Failure of Platinum-Based Chemotherapy.

Trial Profile

A Single Arm, Multicenter, Phase II Trial of RAD001 [everolimus] as Monotherapy in the Palliative Treatment of Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma After Failure of Platinum-Based Chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Aug 2017 This trial has been Discontinued in Belgium, according to European Clinical Trials Database.
    • 24 Mar 2012 Additional trial location added as reported by European Clinical Trials Database.
    • 23 Jan 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top